London, June 13, 2026, 21:03 BST
- Haleon shares closed up in London on Friday. The stock trailed the FTSE 100.
- Haleon’s H1 2026 results are due July 30, the next big catalyst.
- Buybacks and growth in oral-health help the bull case. Risks still include U.S. demand, weak cold-and-flu trends, and cost pressure.
Haleon PLC finished Friday’s London session up 0.84% at about 336.8p. The stock hit an intraday high of 337.4p, according to AJ Bell, as the FTSE 100 added 1.63%. There were about 19.0 million shares traded. Haleon’s market cap stands near £29.74 billion. The P/E ratio was 18.21, per AJ Bell, a standard measure comparing share price to earnings.
Haleon (Sensodyne, Panadol) has seen shares trade mostly on Friday’s market rally and its ongoing buyback plan, with no major earnings updates in recent sessions. The group is listed in London and New York. Investors have also been watching the credibility of Haleon’s 2026 guidance. Its U.S. ADRs finished Friday nearly flat at $9.13, the latest available quote.
Haleon’s stock got its latest push from the company’s share buyback plan. On June 8, Haleon said it bought 16,585,448 ordinary shares for cancellation, sticking to the buyback that started in March. These buybacks can boost earnings per share since they cut the number of shares in the market, but they won’t solve slow revenue growth on their own. Investegate Haleon’s buyback page shows £500 million earmarked for share repurchases for 2026, with a programme for up to that total kicking off March 12.
Debate over Haleon’s outlook goes back to its April Q1 results. Haleon said it brought in £2.86 billion revenue, with 2.2% organic revenue growth. It stuck with its full-year outlook for 3% to 5% organic revenue growth and high-single-digit adjusted operating profit growth at constant currency. Organic revenue growth is meant to show like-for-like sales, cutting out currency and portfolio changes. The adjusted profit growth figure is supposed to reflect profit growth with currency swings removed.
Haleon CEO Brian McNamara said the group turned in “a competitive performance in a challenging market,” with North America back to growth and Oral Health strong, led by Sensodyne and parodontax. Oral Health organic revenue rose 8.3% for the quarter. Respiratory Health, though, fell 3.4% as the cold-and-flu season came in weak. The company said that hit quarterly growth by about 130 basis points. A basis point equals one-hundredth of a percent. Haleon Corporate
Haleon’s bull thesis centers on steady cash flow from its branded consumer health line, with buybacks and supply-chain moves expected to drive up per-share earnings. Most analysts are staying positive. Investors Chronicle reports 14 analysts have a median 12-month price target of 422.5p, which is about 25% above the last price of 336.8p. The highest forecast is 512p, the lowest is 325p.
Friday’s gain wasn’t enough to get the stock close to its 416.1p high for the year. The dividend yield is 2.11% and the P/E comes in at 18.21, putting it in the stability camp, not bargain territory. Reuters said Haleon flagged higher freight costs after its Q1 update. Quilter’s Chris Beckett said: “Haleon isn’t a million miles away from being a very good story, but it needs more than the toothpaste business to start performing.” AJ Bell
Haleon is showing some appeal on today’s numbers, but it’s not a clear value play. The buyback, analysts’ price targets, and oral-health tailwinds are in its favor. Still, the real upside hinges on a rebound in North America and gains outside toothpaste. Holding up margins under cost pressure is also key. The H1 2026 results, set for July 30, are the next big event—investors want to see proof of faster growth after Q1’s slow patch.
